A Phase 1 Study of XmAb819 in People with Kidney Cancer

Share

Full Title

A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAbTM819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Purpose

In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.

XmAb819 is a type of immunotherapy called a T-cell engaging bispecific antibody (BiTE). It targets ENPP3, a protein that is made in large amounts in kidney cancers. This treatment is designed to help your immune system fight cancer cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have clear cell renal cell cancer that keeps growing even though you had treatment, including prior immunotherapy.
  • Have completed previous cancer treatment at least 4 weeks before getting XmAb819.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Ritesh Kotecha’s office at 646-422-4839.

Protocol

22-421

Phase

Phase I (phase 1)

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

ClinicalTrials.gov ID

NCT05433142